Related Experiment Video
Updated: Jun 17, 2026
09:15
Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers
Published on: July 19, 2024
Dasatinib
Markus Lindauer1, Andreas Hochhaus
1Medizinische Klinik III, SLK-Kliniken Heilbronn GmbH, Am Gesundbrunnen 20-26, Heilbronn, 74078, Germany. markus.lindauer@slk-kliniken.de
Summary
Dasatinib is a potent multikinase inhibitor effective against BCR-ABL and SRC-family kinases. It shows significant efficacy in treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, especially in imatinib-resistant cases.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Dasatinib is an orally available small-molecule multikinase inhibitor.
- It targets BCR-ABL and SRC-family kinases, c-KIT, PDGFR, and ephrin receptor kinase.
- Dasatinib exhibits superior potency compared to imatinib against unmutated BCR-ABL in vitro.
Purpose of the Study:
- To evaluate the efficacy and safety of dasatinib in treating BCR-ABL-positive malignancies.
- To assess dasatinib's activity against imatinib-resistant mutations.
- To determine optimal dosing regimens for different phases of CML and ALL.
Main Methods:
- Clinical trials evaluating dasatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Assessment of hematologic, molecular, and cytogenetic remission rates.
- Monitoring of adverse events and side effects.
Main Results:
- High rates of hematologic and molecular remission and prolonged survival in chronic phase CML with a 100 mg daily dose.
- Complete hematologic and cytogenetic remissions observed in accelerated and blast phase CML and ALL with 70 mg twice daily, though remissions were short-lived.
- Common side effects include cytopenias and pleural effusions, generally manageable.
Conclusions:
- Dasatinib is an effective treatment for imatinib-resistant or intolerant CML and Ph+ ALL.
- Specific dosing regimens are recommended based on disease phase and type.
- While effective, careful monitoring for side effects is necessary.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...